Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prospects for bioreductive drug development.

R M Phillips1

  • 1Clinical Oncology Unit, University of Bradford, Bradford, BD7 1DP, UK.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polymer encapsulation of anticancer silver-N-heterocyclic carbene complexes.

RSC advances·2022
Same author

Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid Models.

The Journal of pharmacology and experimental therapeutics·2019
Same author

Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.

Expert opinion on drug metabolism & toxicology·2017
Same author

Drug delivery in a tumour cord model: a computational simulation.

Royal Society open science·2017
Same author

Synthesis and anticancer activity evaluation of η(5)-C5(CH3)4R ruthenium complexes bearing chelating diphosphine ligands.

Dalton transactions (Cambridge, England : 2003)·2015
Same author

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways.

Oncogenesis·2014

Bioreductive drugs are inactive prodrugs activated in low-oxygen tumor environments. This review assesses novel drug development and strategies to optimize bioreductive drug activity for cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Bioreductive drugs are prodrugs activated to cytotoxins under hypoxia or high reductase levels.
  • Tumor hypoxia and specific reductase levels offer selective activation, but ideal drug criteria remain challenging.
  • Mitomycin C is the sole clinically used bioreductive drug; tirapazamine shows promise, while others require further development.

Purpose of the Study:

  • To critically assess recent developments in bioreductive drug discovery and optimization strategies.
  • To highlight novel approaches like gene-directed enzyme prodrug therapy (GDEPT) for exploiting tumor hypoxia.
  • To review advancements in hypoxia detection and combination therapies.

Main Methods:

  • Review of current bioreductive drug development stages and clinical evaluations.

Related Experiment Videos

  • Analysis of novel therapeutic strategies including GDEPT and hypoxia markers.
  • Assessment of combination therapies involving bioreductive drugs, photodynamic therapy, and nitric oxide synthase inhibitors.

    • Main Results:

    • Tirapazamine demonstrates clinical activity in combination therapy for solid tumors.
    • Development of hypoxia-responsive promoters for GDEPT and improved hypoxia markers are progressing.
    • Synergistic effects observed with combination therapies suggest enhanced efficacy.

    Conclusions:

    • Bioreductive drug development requires multidisciplinary expertise for clinical utility.
    • Optimizing drug delivery and targeting hypoxic tumor regions are crucial for efficacy.
    • Further research into novel strategies and combination therapies is essential for advancing bioreductive drug use in oncology.